These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 26015868)

  • 1. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs.
    Marquard AM; Eklund AC; Joshi T; Krzystanek M; Favero F; Wang ZC; Richardson AL; Silver DP; Szallasi Z; Birkbak NJ
    Biomark Res; 2015; 3():9. PubMed ID: 26015868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    Watkins JA; Irshad S; Grigoriadis A; Tutt AN
    Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
    Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
    Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
    Chao A; Lai CH; Wang TH; Jung SM; Lee YS; Chang WY; Yang LY; Ku FC; Huang HJ; Chao AS; Wang CJ; Chang TC; Wu RC
    J Mol Med (Berl); 2018 Jun; 96(6):527-536. PubMed ID: 29725737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
    Gou R; Dong H; Lin B
    Life Sci; 2020 Nov; 261():118434. PubMed ID: 32941897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation.
    Sahajpal NS; Mondal AK; Vashisht A; Singh H; Pang AWC; Saul D; Nivin O; Hilton B; DuPont BR; Kota V; Savage NM; Hastie AR; Chaubey A; Kolhe R
    Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas.
    Manié E; Popova T; Battistella A; Tarabeux J; Caux-Moncoutier V; Golmard L; Smith NK; Mueller CR; Mariani O; Sigal-Zafrani B; Dubois T; Vincent-Salomon A; Houdayer C; Stoppa-Lyonnet D; Stern MH
    Int J Cancer; 2016 Feb; 138(4):891-900. PubMed ID: 26317927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
    Isakoff SJ; Mayer EL; He L; Traina TA; Carey LA; Krag KJ; Rugo HS; Liu MC; Stearns V; Come SE; Timms KM; Hartman AR; Borger DR; Finkelstein DM; Garber JE; Ryan PD; Winer EP; Goss PE; Ellisen LW
    J Clin Oncol; 2015 Jun; 33(17):1902-9. PubMed ID: 25847936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
    BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    Takamatsu S; Brown JB; Yamaguchi K; Hamanishi J; Yamanoi K; Takaya H; Kaneyasu T; Mori S; Mandai M; Matsumura N
    JCO Precis Oncol; 2022 May; 6():e2200085. PubMed ID: 35613413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential value of the homologous recombination deficiency signature we developed in the prognosis and drug sensitivity of gastric cancer.
    Wu X; Wang Q; Liu P; Sun L; Wang Y
    Front Genet; 2022; 13():1026871. PubMed ID: 36468004
    [No Abstract]   [Full Text] [Related]  

  • 13. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
    Birkbak NJ; Wang ZC; Kim JY; Eklund AC; Li Q; Tian R; Bowman-Colin C; Li Y; Greene-Colozzi A; Iglehart JD; Tung N; Ryan PD; Garber JE; Silver DP; Szallasi Z; Richardson AL
    Cancer Discov; 2012 Apr; 2(4):366-375. PubMed ID: 22576213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers for Homologous Recombination Deficiency in Cancer.
    Hoppe MM; Sundar R; Tan DSP; Jeyasekharan AD
    J Natl Cancer Inst; 2018 Jul; 110(7):704-713. PubMed ID: 29788099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
    Vanderstichele A; Busschaert P; Olbrecht S; Lambrechts D; Vergote I
    Eur J Cancer; 2017 Nov; 86():5-14. PubMed ID: 28950147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors.
    Ma J; Shah R; Bell AC; McDermott N; Pei X; Selenica P; Haseltine J; Delsite R; Khan AJ; Lok BH; Ellis MJ; Aft RF; Setton J; Reis-Filho JS; Riaz N; Powell SN
    Int J Radiat Oncol Biol Phys; 2024 Jul; ():. PubMed ID: 38997095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD).
    Rempel E; Kluck K; Beck S; Ourailidis I; Kazdal D; Neumann O; Volckmar AL; Kirchner M; Goldschmid H; Pfarr N; Weichert W; Hübschmann D; Fröhling S; Sutter C; Schaaf CP; Schirmacher P; Endris V; Stenzinger A; Budczies J
    NPJ Precis Oncol; 2022 Jun; 6(1):36. PubMed ID: 35681079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do platinum salts fit all triple negative breast cancers?
    Gerratana L; Fanotto V; Pelizzari G; Agostinetto E; Puglisi F
    Cancer Treat Rev; 2016 Jul; 48():34-41. PubMed ID: 27343437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.
    Watkins J; Weekes D; Shah V; Gazinska P; Joshi S; Sidhu B; Gillett C; Pinder S; Vanoli F; Jasin M; Mayrhofer M; Isaksson A; Cheang MC; Mirza H; Frankum J; Lord CJ; Ashworth A; Vinayak S; Ford JM; Telli ML; Grigoriadis A; Tutt AN
    Cancer Discov; 2015 May; 5(5):488-505. PubMed ID: 25770156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.